A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies von Curigliano, G., Jimenez, M.M., Shimizu, T., Keam, B., Meric-Bernstam, F., Rutten, A., Glaspy, J., Schuler, P.J., Parikh, N.S., Ising, M., Hassounah, N., Wu, J., Leyk, M., Chen, X., Burks, H., Chaudhury, A., Otero, J., Cabanas, E.Garralda

Volltext